MedTrace Logo

A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma

NCT04038359 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.

Conditions

  • Indolent Non-Hodgkin Lymphoma

Interventions

DRUG

Duvelisib

Phosphoinositide 3-kinase (PI3K) inhibitor

Sponsors & Collaborators

  • SecuraBio

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2023-07-24
Completion
2023-07-24
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Germany
  • Italy
  • Poland
  • Russia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04038359 on ClinicalTrials.gov